When: Weekly close below $260 on volume >6M

Then: Reassess toward Underweight

When: Q3 earnings miss with soft guide and Stelara erosion acceleration

Then: Reassess toward Underweight

When: Weekly close below $239 (200 SMA) on volume >7M

Then: Escalate toward Sell

When: Adverse talc verdict >$5B

Then: Escalate toward Sell

When: Forward EPS revision toward $10-11

Then: Escalate toward Sell

HOLD; maintain current weight, do not add, trim toward target weight on retest of $270-272 if overweight; require Q3 earnings clarity before fresh capital deployment; entry zone $245-$250 with $260 stop on fresh capital.

• HOLD is correct due to high-quality defensive characteristics (60+ year dividend record, fortress balance sheet, 0.235 beta) combined with five binary Q3 earnings risks that make fresh capital deployment at $267 inadvisable
• Entry zone $245-$250 and $260 stop represent disciplined risk management, not pessimistic anchoring—200 SMA untested in 10 weeks is a reason to respect it as a logical support target
• 31x trailing earnings multiple facing compression: price action since Sep 3 reflects multiple contraction, and 2% dividend yield fails relative-yield test against 4.7% risk-free rate
• Five Q3 disappointment vectors: Stelara erosion (steep part of curve, not back half), Tremfya vs Skyrizi share dynamics, Section 232 tariff exposure, litigation accrual sizing, Caplyta ramp post-$14.6B acquisition
• ATR compression from $6.30 to $5.20 with narrowing Bollinger bands does not automatically resolve upward—50 SMA test on modest 5.57M shares is not bullish confirmation
• Macro setup of 96% no rate cuts and 8% recession probability provides neither multiple expansion tailwind nor defensive-flow tailwind
• Structural quality (defensive beta, covered payout) is the reason to wait for clarity, not a reason to add aggressively—patience is the primary edge in defensive names
• JNJ trades at $267.57 (intraday low $265.59), with recent lower highs at $278, $275, $271, $272

→ vs aggressive: The 'coiled spring' thesis lacks statistical support—ATR compression and Bollinger narrowing do not guarantee upward resolution, and modest volume (5.57M shares) on 50 SMA test is not bullish confirmation but rather a quiet tape that can precede orderly drift lower

→ vs aggressive: PEG normalization to 1.6-1.7 via talc charge exclusion still represents fair value for a name without execution certainty heading into Q3, not a compelling entry signal

→ vs aggressive: The Treasury comparison argument ('JNJ doesn't compete for marginal flow') fails in a regime where 30-year yields at 2002 highs create relative-yield screening pressure from income allocators even without literal rotation

→ vs aggressive: No rate cuts (96% probability) means no multiple expansion catalyst, and 8% recession probability means no defensive-flow bid—'baked in' is already reflected in the multiple compression since Sep 3

→ vs aggressive: Calling the 50 SMA hold a 'structural floor' after a single day's intraday wick is confirmation bias that gets investors 'crushed'—three weeks of lower highs preceded this level

HOLD

• HOLD is the appropriate rating; structural quality justifies maintaining position through catalyst window but doesn't justify fresh capital deployment at $267
• Q3 earnings in mid-October with Section 232 tariff uncertainty as a separate binary event is the binding constraint on the decision
• Valuation debate (PEG normalization, talc impact) is interesting but not the binding constraint for the next 4-6 weeks
• Macro setup is neutral—no rate cuts means no multiple expansion, not a tailwind
• Entry zone should be conditional on Q3 earnings print quality rather than anchored to a specific price level
• Trim toward target weight on any retest of $270-$272 if currently overweight is the most defensible tactical element
• Stop at $260 is too tight for a coiled name with ATR at $5.20; stops should protect against structural break below $262 but allow normal post-earnings volatility
• JNJ's defensive characteristics give optionality on post-earnings setup regardless of direction—that is the actual edge
• A $644B mega-cap with 0.235 beta is not primarily driven by pension fund and retiree marginal flows; Treasury comparison headwind is slow-moving, not near-term catalyst
• The coiled spring argument has merit but distribution can look like orderly drift in defensive names on indifferent volume

→ vs aggressive: Coiled spring volatility compression argument is emotionally compelling but statistically undercooked—a tendency with counterexamples, not a market law

→ vs aggressive: Framing 'no multiple compression' as equivalent to 'multiple expansion' is incorrect; a 31x trailing multiple needs earnings growth to justify itself

→ vs aggressive: $245-$250 target zone hasn't been justified versus $255-$260 where Bollinger lower band and prior consolidation sit

→ vs conservative: Stop at $260 with entry at $247.50 is 4.6% risk, too tight for a coiled name with $5.20 ATR; that pre-commits to getting shaken out

→ vs conservative: Treasury comparison and relative-yield pressure argument overstates compression risk for a $644B mega-cap; it's a slow-moving structural headwind, not a near-term catalyst

→ vs conservative: 50 SMA test on 5.57 million shares with modest volume isn't a structural confirmation event—it's a wick on quiet tape

→ vs conservative: JNJ doesn't compete with 30-year Treasuries for marginal flow; buyer base is more diversified than pension funds and retirees